openPR Logo
Press release

Antidiabetics Market Intelligence with Competitive Landscape 2023

10-09-2017 04:37 PM CET | Advertising, Media Consulting, Marketing Research

Press release from: Transparency Market Research

/ PR Agency: Transparency Market Research
Antidiabetics Market Intelligence with Competitive Landscape

The anti-diabetics market includes drugs, which are used for treatment of diabetes mellitus and are also known as oral hypoglycemic/antihyperglycemic agents. The anti-diabetics market has grown tremendously in recent years with increasing prevalence of diabetes mellitus. Thus, systemic therapies for diabetes have become the focal point of attention due to the burgeoning diabetic population size, with diabetes affecting middle age groups and children across all income groups globally.

The anti-diabetics market has been segmented based on type of drug class into biguanides (metformin), sulfonylureas (glimepiride), meglitinides (repaglinide), thiazolidinediones (pioglitazone), dipeptidyl peptidase IV (DPP-IV) inhibitors (sitagliptin), and α-glucosidase inhibitors (acarbose). 

Request Sample Copy of the Report@

 https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=8809

 

Among these drug classes, Biguanides act directly against insulin resistance. Sulfonylureas (SUs) were the earliest drug classes in the market for treatment of diabetes and have a significant market presence. α-glucosidase inhibitors delay postprandial glucose absorption by hydrolysis of disaccharide is into monosaccharide’s in the small intestine.  Meglitinides are prandial insulin releasers that stimulate rapid insulin secretion. The thiazolidinediones are insulin-sensitizing drugs, which improve whole-body insulin sensitivity through gene regulation. DPP-IV inhibitors make a significant impact on glucose tolerance and make lasting improvements in the health outcomes of diabetic patients. 

Some of the major drivers and opportunities for growth of this market include drug combinations of several agents such as sitagliptin and metformin and other drug combinations that are in different stages of clinical and pipeline development. Increase in the prevalence of diabetes and new product launches by major pharmaceutical companies re some of the key drivers for growth in this market. In 2015, Boehringer Ingelheim GmbH launched two new drugs (Synjardy & Glyxambi)for treatment of diabetes mellitus type II. 

Some of the key opportunities for the antidiabetics include a strong pipeline for antidiabetics and entry of new players in the market, for instance, Novo Nordisk's diabetes drug’s Tresiba, and Ryzodeg received FDA approval in September 2015. Moreover, Boehringer Ingelheim GmbH has a strong pipeline for anti-diabetic drugs, such as Linagliptin which is a dipeptidyl peptidase (DPP) 4 inhibitor) for patients suffering from diabetes mellitus type II and high cardiovascular risk. 

However, despite the availability of numerous branded antidiabetic drugs, many of these drugs have lost patent protection. In the wake of huge pressures from government and regulatory authorities, which have banned top selling drugs in various countries, in order to promote generic drugs at lower costs for diabetic patients. For instance, Mankind Pharma, launched anti-diabeticDynaglipt (Teneligliptin) under the drug class DPP-4 inhibitors in November 2015 in India targeting the middle to low income diabetic patient population. 

As a result, the volume of antidiabetics is expected to shift to first generation drugs and other generic drugs in the market. Moreover, there is a huge unmet medical need for antidiabetics that can treat multiple chronic disorderscoexisting with diabetessuch as cardiovascular diseases, dyslipidemia, hypertension etc. Another major restraint in the antidiabetics market is reduction in the efficacy of drugs over a period and canlead to other health complications.

Request TOC of the Report@

https://www.transparencymarketresearch.com/sample/sample.php?flag=T&rep_id=8809 

 

Some of the major players in the market include Astra Zeneca plc, Boehringer Ingelheim GmbH, Eli Lilly & Co., Johnson & Johnson, Mankind Pharma Ltd., Merck & Co. Inc., Novartis AG, Novo Nordisk A/S, SanofiS.A., and Teva Pharmaceutical Industries Ltd.

This research report analyzes this market on the basis of its market segments, major geographies, and current market trends. This report provides comprehensive analysis of 

Market growth drivers 
Factors limiting market growth
Current market trends 
Market structure
Market projections for upcoming years 

About Us

Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of Analysts, Researchers, and Consultants, use proprietary data sources and various tools and techniques to gather and analyze information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

Contact Us

Transparency Market Research
90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA – Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: www.transparencymarketresearch.com/

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Antidiabetics Market Intelligence with Competitive Landscape 2023 here

News-ID: 763635 • Views: 169

More Releases from Transparency Market Research

Automotive Gasket and Seal Market is projected to be valued at a US$21.4 bn by 2 …
The global automotive gasket and seal market is foretold to gain prominence with a snowballing emphasis on the design of effective and superior products that involve the application of top-quality material to endure high pressure and heat. The rising pressure on the automotive sector owing to environmental concerns and changes is pushing vehicle manufacturers to develop improved and innovative components. In this regard, new gaskets and seals could draw a
Impact Of Covid-19 Outbreak On Train Control and Management Systems Market
The global train control and management system market is highly competitive and fragmented, states a new study by Transparency Market Research (TMR). The top four companies, namely, Bombardier Inc., Alstom S.A., Siemens AG, and Toshiba Corp. could occupy a share of nearly 45% only in this market in 2015. With the rising number of new entrants, the competition within the market is likely to intensify in the near future. Obtain
ANALYSIS OF POTENTIAL IMPACT OF COVID-19 ON HOSPITAL ASSET MANAGEMENT MARKET
Set to chart a robust growth rate of about 12% (CAGR) from 2018 to 2026, the global hospital asset management market is on an upward trajectory. By the end of the forecast period, the market would have grown to a value of USD 15 billion from its value of USD 6 billion in the year of 2018. It is significant to note here that the market is witnessing growth in both
The Effects of the COVID-19 Outbreak On Antimicrobial Packaging Market
A noticeable rise in the microbial infestation of various packaged food products are supporting the growth of the global antimicrobial packaging market. Several stringent rules and regulations have been implemented to ensure the quality of the packaged food. Makers of packaged food products are bound by these strict rules as laid down by the relevant authorities across the globe. Obtain Report Details @ https://www.transparencymarketresearch.com/antimicrobial-packaging-market.html The Dow Chemical Company, Linpac Senior Holdings, Oplon

All 5 Releases


More Releases for DPP

Excellent Growth of DPP-IV Inhibitors Market 2019-2023 | Industry Players, Finan …
The report segments the DPP-IV Inhibitors Market by Type, CAGR value, Trends, Approach, Market Size, and Region. A detailed analysis of the key industry players has been done to render key insights into their overviews, services, strategies, service launches, partnerships, agreements, collaborations and business expansions DPP-IV Inhibitors Market, 2018-2023: The report will assist the market leaders/new entrants in the hundreds of ways. The report segments the DPP-IV Inhibitors market thoroughly and
DPP IV Inhibitors Market to Flourish with an Impressive CAGR by 2021
DPP IV inhibitors are a class of hypoglycemic agents that block the enzyme named dipeptidyl peptidase IV. Dipeptidyl peptidase IV enzyme break down the proteins that are responsible for stimulating the insulin producing cells that slows down gastric secretion. Proteins can activate the release of insulin and can control the blood sugar level if DPP IV is inhibited in our body. Moreover, DPP IV inhibitors restrict the formation of glucagon,
DPP IV Inhibitor Market Size to Expand Significantly by the End of 2021
DPP IV inhibitors are a class of hypoglycemic agents that block the enzyme named dipeptidyl peptidase IV. Dipeptidyl peptidase IV enzyme break down the proteins that are responsible for stimulating the insulin producing cells that slows down gastric secretion. Proteins can activate the release of insulin and can control the blood sugar level if DPP IV is inhibited in our body. Moreover, DPP IV inhibitors restrict the formation of glucagon,
DPP IV Inhibitors Market: Latest Innovations, Drivers and Industry Key Events 20 …
DPP IV inhibitors are a class of hypoglycemic agents that block the enzyme named dipeptidyl peptidase IV. Dipeptidyl peptidase IV enzyme break down the proteins that are responsible for stimulating the insulin producing cells that slows down gastric secretion. Proteins can activate the release of insulin and can control the blood sugar level if DPP IV is inhibited in our body. Get access to full summary @: http://www.persistencemarketresearch.com/market-research/dpp-iv-inhibitors-market.asp Moreover, DPP IV
Global DPP IV Inhibitor Market Research Report Forecast 2017 to 2021
Report Hive Market Research Released a New Research Report of 120 pages on Title " Global DPP IV Inhibitor Market Research Report Forecast 2017 to 2021 "with detailed Analysis, Forecast and Strategies. The Global DPP IV Inhibitor Market Research Report Forecast 2017-2021 is a valuable source of insightful data for business strategists. It provides the DPP IV Inhibitor industry overview with growth analysis and historical & futuristic cost, revenue, demand and
DPP IV Inhibitors Market Set to Surge Significantly by 2021
DPP IV inhibitors are a class of hypoglycemic agents that block the enzyme named dipeptidyl peptidase IV. Dipeptidyl peptidase IV enzyme break down the proteins that are responsible for stimulating the insulin producing cells that slows down gastric secretion. Proteins can activate the release of insulin and can control the blood sugar level if DPP IV is inhibited in our body. Moreover, DPP IV inhibitors restrict the formation of glucagon,